Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 plus Famitinib in Advanced Solid Tumors
NCT04679038Phase 2Unknown
- Sponsor
- Hengrui
- Start
- Mar 2021
- Primary completion
- Dec 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in biliary tract carcinoma (BTC), clear cell renal cell carcinoma (ccRCC), hepatocellular carcinoma (HCC), solid tumor, sponsored by Hengrui. Status: unknown.
02
Drugs
retlirafusp alfa
03
Conditions
biliary tract carcinoma (BTC)clear cell renal cell carcinoma (ccRCC)hepatocellular carcinoma (HCC)solid tumor
Beyond the preview
Go deeper on NCT04679038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679038.